AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

Meningiomas are the most common primary brain tumor. They arise from the membranes surrounding the brain and spinal cord and ...

Robot-assisted training with a lightweight exosuit may help patients with advanced heart failure walk more and help them stay ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

While you're collecting healthy dividends, you'll also benefit from the price-to-earnings (P/E) ratio expanding when revenue ...

PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.

FDA approves Depo-Provera label warning of meningioma brain tumor risk after 1983 studies; 1,000+ women sue Pfizer for ...

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...

FDA approves a new Depo-Provera warning on meningioma risk as Pfizer faces lawsuits alleging delayed disclosure of brain ...

The Department of Health says there is "no shortage" of Pfizer COVID-19 vaccines in New Brunswick, but with holiday ...